Dear Editor in chief, We read with great interest the paper from Vanderhaegen et al. analyzing the impact of the COVID-19 pandemic on the timing of Head & Neck Cancer Patients (HNCP) management. Compared to the pre-pandemic, authors did not report any significant difference in tumor stage before, during, and after lockdown, while the diagnosis-to-treatment interval did not change in the three periods [1]. We strongly agree with the authors that finding a balance between the appropriate management of HNCP and the prevention of patients’ and healthcare workers’ contagion has been and is going to be very challenging [2]. To assess the effective burden of the COVID-19 pandemic on HNCP management, we retrospectively reviewed clinical data of HNCP that were evaluated by the Head & Neck Multidisciplinary Tumor Board of our University Hospital (Firenze, Italy) before (October 1st, 2019–February 28th, 2020) and after (March 1st, 2020–December 31st, 2020) SARS-CoV-2 outbreak. Overall, 268 HNCP were enrolled, of whom 81 were treated before (30.2%) and 187 during the pandemic (69.8%). Specifically, cancer subsites before and during the pandemic included respectively 30 and 83 oral cavity, 13 and 26 larynx, 15 and 20 pharynx, 0 and 2 parapharyngeal space, 11 and 26 sinonasal cavities, 0 and 4 orbital cavity, 11 and 18 major salivary glands, 1 and 8 skin. Contrary to the authors, we found a considerably higher percentage of III-IV stage tumors during the pandemic (52.9%) compared to the pre-pandemic period (30.9%, P = 0008). Unavoidable isolation or quarantine for COVID-19 cases or contacts, as well as patients’ reluctance to seek care in closed and crowded places as hospitals are, may have led to delayed diagnosis [1], [3], [4]. Despite most health supplies and anesthesiological personnel being addressed to COVID-19 care, we did not find any statistically significant difference in the diagnosis-to-treatment interval for HNCP before and after the pandemic burst. The complete interruption of non-oncological elective surgery in the “hottest” pandemic periods has strongly contributed to the maintenance of our usual oncological standard of care, while we recognize that the COVID-19 pandemic may have had a higher specific weight on smaller centers with limited resources and on major oncological institutes that monthly deal with dozens of HNCP. Conclusive data on tumor recurrence and survival of HNCP treated during the pandemic may not be deduced because of the short follow-up period [5]. With this in mind, we have been planning a stricter than usual follow-up to detect recurrences as early as possible. Nowadays, inpatient and surgical activity should gradually come back to normality, with the full awareness that the hospital organization should vary as rapidly as COVID-19 epidemiology evolves. The certainty is that, if we join forces all together, a high standard of oncological care may be guaranteed, even in such a critical era.
Letter in reply to “the first wave of COVID-19 did not cause longer wait times in head and neck cancer. Experience of a French expert center” by Vanderhaegen et al. Ann Otorhinolaryngol Head Neck Dis 2022; 139:261-267 / Orlando, P., Licci, G., Maggiore, G., Gallo, O.. - In: EUROPEAN ANNALS OF OTORHINOLARYNGOLOGY, HEAD AND NECK DISEASES. - ISSN 1879-7296. - ELETTRONICO. - 140:(2023), pp. 0-0. [10.1016/j.anorl.2023.02.008]
Letter in reply to “the first wave of COVID-19 did not cause longer wait times in head and neck cancer. Experience of a French expert center” by Vanderhaegen et al. Ann Otorhinolaryngol Head Neck Dis 2022; 139:261-267
Orlando, P.
Membro del Collaboration Group
;Licci, G.;Maggiore, G.;Gallo, O.
2023
Abstract
Dear Editor in chief, We read with great interest the paper from Vanderhaegen et al. analyzing the impact of the COVID-19 pandemic on the timing of Head & Neck Cancer Patients (HNCP) management. Compared to the pre-pandemic, authors did not report any significant difference in tumor stage before, during, and after lockdown, while the diagnosis-to-treatment interval did not change in the three periods [1]. We strongly agree with the authors that finding a balance between the appropriate management of HNCP and the prevention of patients’ and healthcare workers’ contagion has been and is going to be very challenging [2]. To assess the effective burden of the COVID-19 pandemic on HNCP management, we retrospectively reviewed clinical data of HNCP that were evaluated by the Head & Neck Multidisciplinary Tumor Board of our University Hospital (Firenze, Italy) before (October 1st, 2019–February 28th, 2020) and after (March 1st, 2020–December 31st, 2020) SARS-CoV-2 outbreak. Overall, 268 HNCP were enrolled, of whom 81 were treated before (30.2%) and 187 during the pandemic (69.8%). Specifically, cancer subsites before and during the pandemic included respectively 30 and 83 oral cavity, 13 and 26 larynx, 15 and 20 pharynx, 0 and 2 parapharyngeal space, 11 and 26 sinonasal cavities, 0 and 4 orbital cavity, 11 and 18 major salivary glands, 1 and 8 skin. Contrary to the authors, we found a considerably higher percentage of III-IV stage tumors during the pandemic (52.9%) compared to the pre-pandemic period (30.9%, P = 0008). Unavoidable isolation or quarantine for COVID-19 cases or contacts, as well as patients’ reluctance to seek care in closed and crowded places as hospitals are, may have led to delayed diagnosis [1], [3], [4]. Despite most health supplies and anesthesiological personnel being addressed to COVID-19 care, we did not find any statistically significant difference in the diagnosis-to-treatment interval for HNCP before and after the pandemic burst. The complete interruption of non-oncological elective surgery in the “hottest” pandemic periods has strongly contributed to the maintenance of our usual oncological standard of care, while we recognize that the COVID-19 pandemic may have had a higher specific weight on smaller centers with limited resources and on major oncological institutes that monthly deal with dozens of HNCP. Conclusive data on tumor recurrence and survival of HNCP treated during the pandemic may not be deduced because of the short follow-up period [5]. With this in mind, we have been planning a stricter than usual follow-up to detect recurrences as early as possible. Nowadays, inpatient and surgical activity should gradually come back to normality, with the full awareness that the hospital organization should vary as rapidly as COVID-19 epidemiology evolves. The certainty is that, if we join forces all together, a high standard of oncological care may be guaranteed, even in such a critical era.I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.



